Quick Facts: Primary Uses

• Supports the management of heartburn and other symptoms related to Gastroesophageal Reflux Disease (GERD).
• Assists in the healing of damage to the esophagus caused by acid reflux (erosive esophagitis).
• Contributes to the treatment and maintenance of both stomach (gastric) and intestinal (duodenal) ulcers.
• Used in combination with other medications for managing certain bacterial infections (H. pylori) linked to ulcers.
• Helps manage conditions where the stomach produces excessive acid, such as Zollinger-Ellison syndrome.

---

What Lansoprazol Aurobindo Treats: Main Uses and Benefits

Lansoprazol Aurobindo is a medication approved for supporting the reduction of stomach acid in adults and, in some cases, children. Its primary role is to provide relief for conditions aggravated by elevated levels of gastric acid.

This medication is used to support the management of symptoms associated with Gastroesophageal Reflux Disease (GERD), including frequent heartburn and regurgitation. It also assists in promoting the healing of erosive esophagitis, which involves acid-related damage to the lining of the food pipe.

For patients with peptic ulcer disease, the product is indicated for the treatment of active ulcers in the duodenum and stomach. It may also be used for the maintenance of healing of these ulcers. Furthermore, it contributes to the management of gastric ulcers associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and for reducing the risk of their occurrence in high-risk individuals requiring continued NSAID therapy.

Lansoprazol Aurobindo is also indicated for use as part of a therapeutic regimen, alongside antibiotics, to support the elimination of Helicobacter pylori (H. pylori) bacteria, which can be a contributing factor in certain ulcers. This medication is utilized across these specific therapeutic domains to manage acid-related gastrointestinal conditions.

Who can and cannot use Lansoprazol Aurobindo?

This medicine's eligibility is determined by specific rules outlined in official regulatory labeling.

Eligibility Scope	Status (As per Regulatory Documents)
Populations for whom use is Contraindicated
Hypersensitivity to Lansoprazole or Excipients	Contraindicated
Concomitant use with Atazanavir or Nelfinavir	Contraindicated
Infants under 1 year of age	Contraindicated (Safety/Efficacy Not Established)
Specific Hereditary Metabolic Disorders	Contraindicated (e.g., specific formulations with lactose)
Populations for whom use is Not Recommended/Restricted
Severe Hepatic Impairment	Not Recommended (Requires caution/consideration)
Pregnancy	Not Recommended (Use only if potential benefit justifies risk)
Lactation (Breastfeeding)	Not Recommended (Decision to discontinue nursing or drug is required)
Age-Related Eligibility
Adults (18 years and older)	Established/Allowed
Children and Adolescents (1 to 17 years)	Established for specific short-term treatments
Older Adults (Geriatric)	Established/Allowed (No mandatory dose adjustment based on age)
Organ Function Eligibility
Renal Impairment	Established/Allowed (No standard dose adjustment required)

The official eligibility profile is structured by clear contraindications that prohibit use in specific groups, such as infants under one year old and patients taking certain antiretroviral drugs. Use is restricted or not recommended for populations where safety data is limited or physiological clearance is impaired, notably in severe liver impairment and during pregnancy or lactation. For all other established populations, including adults and children over one year, use is permitted under standard labeled conditions.

Interactions with other medicines and products

Lansoprazol Aurobindo (Lansoprazole) interactions are officially documented based on two primary mechanisms: the alteration of gastric pH and its involvement with the CYP2 C19 and CYP3 A4 enzyme systems. This interaction profile establishes several key constraints.

Formal Interaction Restrictions

Co-administration with HIV protease inhibitors such as Atazanavir and Rilpivirine is contraindicated due to the expected significant pH-dependent reduction in exposure of these medicines. Conversely, co-administration with Digoxin may lead to increased plasma levels of Digoxin.

Metabolic and Pharmacokinetic Effects

Lansoprazole's influence on metabolism requires monitoring when used with Warfarin (due to potential for increased INR) and Tacrolimus (due to potential for increased concentrations). CYP enzyme inducers like Rifampicin and St John's Wort can markedly reduce the plasma concentrations of Lansoprazole itself. Titration of the Theophylline dosage may also be required, as Lansoprazole has been shown to reduce its plasma concentration.

Timing and Non-Medicinal Product Interactions

Administration of Lansoprazole must be separated from agents that physically interfere with its absorption. The medicine should be taken at least 1 hour after the administration of Sucralfate or Antacids to prevent a decrease in bioavailability. Furthermore, administration 30 minutes after food results in a diminution of exposure (AUC and Cmax) by 50% to 70%.

Lansoprazole Aurobindo is a substituted benzimidazole that functions as a proton pump inhibitor (PPI), mediating the inhibition of gastric acid secretion. The resulting pharmacological effect is the control of hydrochloric acid production.

Its mechanism involves selective and irreversible binding to the H^+/K^+-ATPase enzyme system (the proton pump) found on the secretory surface of parietal cells in the stomach lining. This chemical reaction occurs following the drug's activation by acid within the secretory canaliculi of the parietal cells. The binding event subsequently inhibits the terminal step in gastric acid production.

This sustained inhibition alters the biochemical environment in the upper gastrointestinal tract by reducing the luminal acid concentration, which limits acid exposure to sensitive mucosal surfaces.

How to Use Lansoprazol Aurobindo: Official Administration Guidelines

Lansoprazole, the active ingredient in this medicine, is administered via the oral route using specialized delayed-release forms such as capsules, orally disintegrating tablets (ODT), or powder for suspension. This medicine must be taken before meals (at least 30 minutes prior to eating) to ensure optimal absorption and effectiveness.

Standard Dosing and Frequency

The standard adult dosing is typically 15 mg or 30 mg taken once daily, with the specific dosage and treatment duration determined by the clinical application. For Helicobacter pylori eradication regimens, a 30 mg dose is often administered twice daily in combination with antibiotics. For pathological hypersecretory conditions, initial daily doses may be higher (60 mg) and are divided if they exceed 120 mg. Treatment duration varies, ranging from short-term courses of 4 to 8 weeks for ulcer healing to continuous use for maintenance therapy.

Procedural and Population-Specific Instructions

The delayed-release capsule and pellets must not be crushed, chewed, or broken, as this compromises the enteric coating and leads to drug inactivation by stomach acid. For patients who cannot swallow the capsule whole, the pellets may be sprinkled onto specific soft foods (e.g., applesauce) or administered through a nasogastric tube using 40 mL of apple juice.

Population-Specific Rules:

Population	Official Dosing Rule
Severe Hepatic Impairment	Recommended dose is 15 mg once daily.
Older Adults	Daily dose should generally not exceed 30 mg.
Missed Dose	Take as soon as remembered, but skip if nearly time for the next dose; do not double doses.

These instructions define the standardized approach to using the medicine.

Research Evidence / Overview of Studies

This section gives an overview of the key clinical research that has evaluated the drug and examined its association with patient outcomes.

---

Condition A: Management and Outcomes

Research has examined the drug in relation to measured changes in symptom indicators for Condition A, which included short-term and longer-term changes in flare-up frequency.

Research has included investigation of the drug's activity on a pathway associated with inflammation in Condition A.

• Phase 1 & 2 Findings: Initial trials investigated the drug’s pharmacokinetics and dose-ranging. Clinical trials have evaluated the occurrence and reporting of adverse events in adult patients.
• Phase 3 Trial Data: The pivotal Phase 3 study was a randomized, double-blind, placebo-controlled trial. Phase 3 data showed an observed difference in outcome when compared to a placebo group. The study assessed the primary endpoint of symptom score changes at 12 weeks.

---

Condition B: Severe Forms

Research has investigated this drug’s profile in relation to measures of reported pain and functional mobility scores in patients with severe forms of Condition B.

• Long-term Efficacy Studies: Some studies followed patients for up to two years. These studies evaluated different starting doses. The long-term profile was evaluated in studies by measuring functional ability and health-related status metrics.
• Current Research Focus: Further research is currently evaluating the drug in trials designed to assess comparison against older treatments for Condition C.

---

Co-existing Conditions

Studies have also explored the drug’s profile in patients with both Condition A and Condition B. Research has examined the co-administration of the drug with standard care (Treatment Z) and evaluated overall results. Findings from these studies contribute to ongoing efforts to understand the drug's profile in complex patient groups.

Common questions about Lansoprazol Aurobindo (FAQ)

---

Q: Is Lansoprazol Aurobindo the same as generic lansoprazole?

Lansoprazol Aurobindo contains the single active ingredient lansoprazole. Regulatory information states that medicines with the same active substance are generally considered equivalent if they meet the same official quality standards. Aurobindo is the manufacturer of this specific version.

---

Q: What are the most common things people take Lansoprazol Aurobindo for?

According to official regulatory indications, this medicine is primarily used to treat conditions involving excessive stomach acid. This includes Gastroesophageal Reflux Disease (GERD), healing and maintenance of erosive esophagitis (damage to the food pipe), and treating duodenal and gastric ulcers.

---

Q: Does Lansoprazol Aurobindo cure acid reflux, or just manage it?

The medicine works by reducing the production of stomach acid to relieve symptoms and allow damaged tissue to heal. It is indicated for the short-term treatment of symptoms and for the maintenance of healing of damaged tissues. Its primary role is to manage symptoms and facilitate the healing process, with use often continuing for maintenance purposes.

---

Q: What research is available on the effectiveness of Lansoprazol Aurobindo?

Regulatory documents include a Clinical Studies section that summarizes the evidence used to support the medicine’s approved uses. This evidence comes from controlled trials that compare the drug's effectiveness and safety to a placebo or other treatments.

---

Q: Are there any specific foods to avoid when taking Lansoprazol Aurobindo?

Official administration guidelines state the medicine should be taken before meals to promote optimal absorption. Taking it after food is noted to reduce its effectiveness. Specific dietary restrictions are typically discussed as part of the overall management plan for the underlying condition.

---

Q: What kind of studies support the use of Lansoprazol Aurobindo for its main indications?

The use of this medicine is supported by data from controlled clinical trials (often randomized and double-blind). These studies evaluate key outcomes like how well symptoms are relieved, the healing rates of ulcers and erosions, and the medicine’s overall safety profile.

---

Q: Does Lansoprazol Aurobindo interact with common supplements like magnesium or calcium?

Official safety information notes that long-term use is associated with a risk of low levels of magnesium in the blood (Hypomagnesaemia). This low magnesium level can sometimes lead to secondary low levels of calcium (hypocalcemia). For patients on prolonged therapy, official guidelines recommend monitoring for these mineral deficiencies.

---

Q: Why do people sometimes use Lansoprazol Aurobindo for throat symptoms?

The medicine is officially indicated for conditions like Gastroesophageal Reflux Disease (GERD) and erosive esophagitis. Since acid moving back up from the stomach can cause symptoms in the throat, the medicine's role in reducing stomach acid helps relieve these upper digestive issues.

---

Q: Does taking Lansoprazol Aurobindo make you more susceptible to stomach infections?

Official safety information notes that proton pump inhibitor therapy may be associated with an increased risk of certain gastrointestinal infections. This includes infections such as Clostridium difficile-associated diarrhea (CDAD).

---

Q: What is the maximum duration for a short-term course of Lansoprazol Aurobindo?

The duration of treatment is determined by the condition being managed. For short-term prescription use for ulcers or inflammation, treatment may last between 4 to 8 weeks. Over-the-counter use for frequent heartburn is typically for a period of 14 days.

---

Q: Can Lansoprazol Aurobindo affect blood sugar levels?

While the medicine itself may not be a primary cause of blood sugar changes, its involvement in certain metabolic pathways (like the CYP enzyme system) means it can interact with other medicines. For example, interaction with some antidiabetic drugs is possible, and such interactions may necessitate adjustments to other medication dosages.

---

Q: Is Lansoprazol Aurobindo used for stomach ulcers as well as reflux?

Yes, regulatory indications confirm that this medicine is used for both conditions. It is indicated for the treatment of acid reflux-related issues and for the short-term treatment of active duodenal and benign gastric ulcers.

Storage Requirements

Lansoprazol Aurobindo delayed-release capsules must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medication must be protected from moisture and should be kept away from high heat and humidity. To maintain stability, the container must be kept tightly closed, and for some presentations, storage in the original package is required. Some bottle presentations have a limited shelf life of three months after first opening.

Disposal and Safety

It is mandatory to store the medicine out of the sight and reach of children. Unused or expired product must be disposed of according to local regulatory guidelines, which typically instruct against throwing the medicine into household waste or wastewater. Disposal usually requires returning the medicine to a pharmacy or authorized collection system.